CC
REGN icon

Courier Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Courier Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-994
Closed -$957K – 352
2024
Q1 		$957K Buy
+994
New +$945K 0.07% 188
2023
Q4 		– Sell
-1,026
Closed -$844K – 361
2023
Q3 		$844K Sell
1,026
-13
-1% -$10.2K 0.07% 186
2023
Q2 		$747K Buy
+1,039
New +$801K 0.06% 203
2020
Q2 		– Sell
-384
Closed -$209K – 274
2020
Q1 		$209K Buy
+384
New +$158K 0.03% 245

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Courier Capital's REGN Position: Q2 2024 in Review

Courier Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 994 shares — an estimated $957K sold.

Courier Capital first reported a position in REGN in Q1 2020 and held it in 4 quarters. The position peaked at $957K in Q1 2024. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Courier Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Courier Capital sold 994 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $957K.
  • Courier Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Courier Capital's Regeneron Pharmaceuticals position peaked at $957K in Q1 2024.
  • 1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Courier Capital's 13F filing for Q2 2024, filed 23 Jul 2024.